<DOC>
	<DOC>NCT02988115</DOC>
	<brief_summary>The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Require lipidmodifying therapy for primary or secondary prevention of cardiovascular disease Fasting LDLC ≥130 mg/dL for primary prevention or LDLC ≥100 mg/dL for secondary prevention (history of HeFH and/or ASCVD) Be statinintolerant (unable to tolerate 2 or more statins) Total fasting triglyceride ≥500 mg/dL Renal dysfunction or nephrotic syndrome or history of nephritis Body Mass Index (BMI) ≥50 kg/m2 Significant cardiovascular disease or cardiovascular event in the past 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>hyperlipidemia</keyword>
	<keyword>cholesterol</keyword>
	<keyword>familial hypercholesterolemia</keyword>
	<keyword>atherosclerotic cardiovascular disease</keyword>
	<keyword>ASCVD</keyword>
	<keyword>HeFH</keyword>
	<keyword>LDL</keyword>
	<keyword>statin intolerence</keyword>
</DOC>